Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
laprituximab emtansine
- Development stage
- Discontinued
- Lead developer
- AbbVie
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
Laprituximab emtansine (IMGN289) is an antibody-drug conjugate (ADC) developed for the treatment of cancers that overexpress the epidermal growth factor receptor (EGFR), such as squamous cell carcinoma of the head and neck (SCCHN) and non-small cell lung cancer (NSCLC). The drug consists of a humanized anti-EGFR monoclonal antibody covalently linked to DM1, a potent maytansinoid cytotoxic agent. Upon intravenous administration, the antibody component binds to EGFR on tumor cells, inhibiting EGFR-mediated signaling and potentially reducing tumor proliferation. The attached DM1 payload enables direct cytotoxicity by disrupting microtubule function in targeted cancer cells. This dual mechanism allows activity against tumors both sensitive and resistant to EGFR inhibition. IMGN289 was designed using ImmunoGen's Targeted Antibody Payload (TAP) technology. IMGN289 development was discontinued after phase 1 trials for solid tumors due to strategic reasons. It showed preclinical efficacy in models resistant to other EGFR inhibitors like cetuximab or gefitinib.
- Other names
- laprituximab emtansine
02
Targets
Beyond the preview
Go deeper on laprituximab emtansine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on laprituximab emtansine.